US · AMLX
Amylyx Pharmaceuticals, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cambridge, MA 02141
- Website
- amylyx.com
Price · as of 2024-12-31
$16.01
Market cap 1.26B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $317.10 | +1,880.64% |
| Intrinsic Value(DCF) | $1.55 | -90.32% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $290.14 | +1,712.24% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $0.00 | $32.87 | |||
| 2021 | $26.01 | $38.13 | |||
| 2022 | $30.66 | $1.97 | $0.00 | ||
| 2023 | $3.36 | $275.65 | $25,005.75 | $10.11 | $1,136.61 |
| 2024 | $3.87 | $317.10 | $0.00 | $0.00 | $290.14 |
AI valuation
Our deep-learning model estimates Amylyx Pharmaceuticals, Inc.'s (AMLX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $317.10
- Current price
- $16.01
- AI upside
- +1,880.64%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.55
-90.32% upside
Graham-Dodd
—
— upside
Graham Formula
$290.14
+1,712.24% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AMLX | Amylyx Pharmaceuticals, I… | $16.01 | 1.26B | +1,881% | -90% | — | +1,712% | -0.87 | 1.60 | 3.02 | -0.31 | — | 1.60 | 51.75% | -360.22% | -345.36% | -100.88% | -1111.62% | -84.87% | 0.01 | — | 6.67 | 6.23 | 0.26 | -73286.00% | -7706.00% | -167149.00% | -63.63% | -5.90 | -593.45% | 0.00% | 0.00% | 0.00% | -0.28 | -0.53 | 1.02 | -2.82 |
| ATAI | Atai Beckley N.V | $3.63 | 684.71M | +564% | -83% | — | — | -1.61 | 2.08 | 785.20 | -1.41 | -0.59 | 2.15 | 100.00% | -33341.23% | -48463.96% | -83.53% | -126.85% | -66.27% | 0.21 | -32.87 | 3.21 | 2.55 | -0.05 | 27200.00% | -191.00% | -257.00% | -34.13% | -3.30 | -102.19% | 0.00% | 0.00% | 0.00% | -1.99 | -2.47 | 663.04 | -4.47 |
| CVAC | CureVac N.V. | $4.66 | 1.05B | +3,460% | -35% | +67% | +15,600% | 3.05 | 0.84 | 1.09 | 0.65 | — | 0.87 | 80.23% | 33.20% | 30.30% | 31.46% | 74.77% | 23.99% | 0.06 | — | 7.28 | 7.16 | -2.11 | -16102.00% | 89554.00% | -12582.00% | 14.31% | 1.41 | 41.31% | 0.00% | 0.00% | 14.10% | 0.77 | 1.64 | 0.25 | 2.92 |
| IMTX | Immatics N.V. | $10.34 | 1.39B | +1,496% | -51% | -32% | +199% | 28.44 | 0.75 | 2.78 | -4.51 | — | 0.76 | 100.00% | -24.78% | 9.77% | 3.80% | 27.69% | 2.52% | 0.03 | -43.58 | 9.26 | 8.99 | -6.40 | -11167.00% | 18860.00% | 127096.00% | -40.32% | -2.32 | 175.55% | 0.00% | 0.00% | 4.04% | 4.03 | 0.89 | -1.00 | 1.96 |
| INBX | Inhibrx Biosciences, Inc. | $74.13 | 1.08B | +370% | -93% | +699% | — | 0.12 | 1.47 | 982.91 | 0.03 | — | 1.47 | -1042.50% | -165724.00% | 843786.00% | 1905.92% | 1880.87% | 690.69% | 0.06 | -24.57 | 3.94 | 3.76 | -0.08 | -237695.00% | -8889.00% | -45.00% | -100.22% | -4.77 | 1117.95% | 0.00% | 0.00% | 39.05% | -0.16 | -0.26 | 260.17 | -3.58 |
| NKTR | Nektar Therapeutics | $68.98 | 1.4B | -92% | -92% | — | — | -1.52 | 2.98 | 1.84 | -0.33 | — | 2.98 | 68.82% | -106.88% | -120.86% | -124.10% | 143.06% | -33.90% | 1.69 | -3.74 | 4.26 | 4.18 | -0.67 | -6017.00% | 922.00% | -842.00% | -97.90% | -2.86 | 241.42% | 0.00% | 0.00% | 15.02% | -0.27 | -0.16 | 0.29 | -16.15 |
| ORIC | ORIC Pharmaceuticals, Inc… | $13.45 | 1.31B | — | — | — | — | -9.41 | 3.17 | — | -7.40 | — | 3.17 | 0.00% | — | — | -41.27% | -272.98% | -37.79% | 0.03 | — | 14.13 | 13.79 | 0.27 | -1967.00% | — | 20.00% | -9.36% | -5.55 | -217.77% | 0.00% | 0.00% | 0.00% | -6.63 | -8.32 | — | 24.72 |
| PGEN | Precigen, Inc. | $3.79 | 1.14B | +633% | -73% | — | +239% | -3.94 | 12.93 | 126.87 | -3.28 | -19.23 | 33.38 | -8.71% | -3440.23% | -3216.18% | -160.80% | -3010.47% | -85.20% | 0.14 | -22504.83 | 4.76 | 4.60 | 0.19 | 2051.00% | -3695.00% | 1211.00% | -15.41% | -3.17 | -1735.60% | 0.00% | 0.00% | 4.73% | -3.00 | -5.28 | 103.33 | -19.72 |
| RLAY | Relay Therapeutics, Inc. | $10.26 | 1.78B | +180% | -62% | — | — | -6.08 | 2.96 | 109.40 | -5.44 | — | 2.96 | 76.83% | -1971.59% | -1800.58% | -41.12% | -108.03% | -37.05% | 0.06 | — | 22.61 | 3.28 | 0.17 | -3178.00% | 5344.00% | -608.00% | -14.04% | -9.21 | -84.17% | 0.00% | 0.00% | 0.06% | -5.38 | -6.90 | 106.04 | 13.52 |
| SANA | Sana Biotechnology, Inc. | $4.21 | 1.12B | — | — | — | — | -2.23 | 2.38 | — | -2.10 | — | 11.75 | 0.00% | — | — | -99.17% | -144.07% | -50.03% | 0.38 | — | 3.54 | 3.36 | 0.13 | -2055.00% | — | -622.00% | -43.07% | -4.91 | -135.54% | 0.00% | 0.00% | 0.66% | -1.97 | -2.09 | — | -4.58 |
| SNDX | Syndax Pharmaceuticals, I… | $21.71 | 1.89B | +262% | +64,186% | — | — | -6.72 | 29.67 | 11.13 | -6.06 | — | 29.67 | 95.96% | -158.45% | -165.60% | -161.82% | 196.12% | -45.50% | 0.00 | -8.08 | 4.40 | 3.60 | 0.54 | -1153.00% | 62784.00% | 1756.00% | -16.85% | -2.69 | 232.09% | 0.00% | 0.00% | 17.03% | -5.58 | -4.71 | 8.84 | -1.10 |
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
- CEO
- Joshua Cohen
- Employees
- 123
- Beta
- -0.30
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.55 ÷ $16.01) − 1 = -90.32% (DCF, example).